Using SABR has also shown oncologic benefit in this population, specifically, in patients with EGFR-negative metastatic NSCLC with up to 5 metastatic sites, with a PFS advantage of 9.7 months compared to 3.5 months in patients managed with maintenance chemotherapy alone [89]. Here, EGFR is linked to non-small cell lung carcinoma.